Zentalis Pharmaceuticals (ZNTL) Enterprise Value (2019 - 2026)

Zentalis Pharmaceuticals' Enterprise Value history runs 8 years deep, the most recent figure standing at -$211.8 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 33.89% year-over-year to -$211.8 million in Q1 2026; TTM through Mar 2026 was -$211.8 million, a 33.89% increase from a year earlier, with the FY2025 full-year figure at -$245.9 million, down 363.29% from the prior year.
• Enterprise Value improved to -$211.8 million in Q1 2026 per ZNTL's latest filing, from -$245.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$27.9 million in Q4 2023 and bottomed at -$320.3 million in Q1 2025.
• The 5-year median for Enterprise Value is -$42.8 million (2022), against an average of -$97.3 million.
• Across the five-year window, Enterprise Value soared 88.89% in 2022 and slumped 751.5% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$42.8 million in 2022, then surged by 34.81% to -$27.9 million in 2023, then slumped by 90.02% to -$53.1 million in 2024, then plunged by 363.29% to -$245.9 million in 2025, then grew by 13.88% to -$211.8 million in 2026.
• Per Business Quant, the three latest ZNTL Enterprise Value figures stand at -$211.8 million (Q1 2026), -$245.9 million (Q4 2025), and -$41.5 million (Q3 2025).